Arsenic Trioxide in Combination with All-Trans Retinoic Acid for the Treatment of Newly Diagnosed Patients with High-Risk APL By Ogkologos - September 3, 2025 467 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the APOLLO study Source RELATED ARTICLESMORE FROM AUTHOR Antitumour Activity of Rezatapopt Provides Proof of Concept for p53 Reactivation in Patients with TP53 Y220C-mutated Solid Tumours Rare Disease Day 2026: Advancing equity for people living with rare cancers in Europe EMA Recommends Extension of Therapeutic Indications for Ponatinib MOST POPULAR Prognostic Role of Plasmatic BRAF Allele Fraction for Survival in Patients... March 27, 2023 Cancer, COVID-19, and Competing Threats to Indigenous Health July 20, 2020 Signal of Increased Risk of Major Cardiovascular Events and Cancer with... June 21, 2021 Abemaciclib Improves PFS at Six Months Among Patients with High-Grade Meningiomas... January 26, 2026 Load more HOT NEWS Women in science: Cancer research pioneers – part 1 Neoadjuvant Ipilimumab Plus Nivolumab Results in Longer EFS Than Adjuvant Nivolumab... Black Women Have Nearly Three Times the Risk of Developing Triple... Nivolumab Plus Chemotherapy Continues to Demonstrate Long-Term Survival Benefits in Patients...
